AI Summary
✦ ClarthaHaleos Labs Limited is an Indian pharmaceutical manufacturer producing active pharmaceutical ingredients and intermediates. Its revenue centers on anti-infective, cardiovascular, gastrointestinal, oncology, and specialty APIs, including anti-ulcer, anti-hypertensive, anti-cancer, and ophthalmic products. Exports extend market reach beyond India. June 2026 standalone sales declined 14.2% year-on-year to ₹67.8 crore, indicating near-term volume or pricing pressure despite improving margins. Profit fell 13.9% year-on-year, while revenue declined 3.2%, although margin improvement suggests better product mix or cost control. ROE is unavailable, preventing assessment of returns on capital; debt-to-equity of 48.15 indicates extreme leverage, which can amplify reported ROE but increases financial risk. At 24.7 times earnings, valuation appears fair against the sector, but not discounted for contracting sales and earnings. The key open question is whether margin gains can offset weak demand and leverage exposure.
Valuation Metrics
Trading 23.7% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.08). Confidence: 68%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
16.05
Current
25.37
Overvalued
22.81
Undervalued
11.79
5Y Average
0.86
Current
1.35
Overvalued
0.98
Undervalued
0.73
5Y Average
8.49
Current
13.43
Overvalued
11.09
Undervalued
5.90
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.3x Undervalued | -25% vs avg | +9.3% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +22.0% | 15.8% | 26.8x Undervalued | -39% vs avg | +20.5% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.9x Undervalued | -19% vs avg | +12.2% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.5x Fair | -13% vs avg | -14.9% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 39.3x Fair | -11% vs avg | +28.1% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 39.0x Fair | -12% vs avg | +31.3% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.2x Fair | +11% vs avg | -1.7% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.4x Premium | +107% vs avg | +115.3% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹68 CrJun 2026Latest net profit
₹3.24 CrJun 2026Latest EPS
₹10.72Jun 2026Net margin
14.2%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 74.56 | 67.84 | 71.23 | 86.37 | 86.57 | 78.50 | 82.88 | 85.43 | 79.04 | 77.84 | 80.72 | 63.38 | 67.83 |
| Expenses + | 69.43 | 58.36 | 62.21 | 75.56 | 72.80 | 66.71 | 69.81 | 79.83 | 68.21 | 67.04 | 69.16 | 57.18 | 58.19 |
| Operating Profit | 5.13 | 9.48 | 9.02 | 10.81 | 13.77 | 11.79 | 13.07 | 5.60 | 10.83 | 10.80 | 11.56 | 6.20 | 9.64 |
| OPM % | 6.88% | 13.97% | 12.66% | 12.52% | 15.91% | 15.02% | 15.77% | 6.56% | 13.70% | 13.87% | 14.32% | 9.78% | 14.21% |
| Other Income + | 0.58 | 0.33 | 0.64 | 2.28 | 0.43 | 1.26 | 0.06 | 2.20 | 1.01 | 0.44 | 0.08 | 0.97 | 0.46 |
| Interest | 1.82 | 2.48 | 2.04 | 2.56 | 2.16 | 1.92 | 1.96 | 1.84 | 1.73 | 1.51 | 1.46 | 1.34 | 1.81 |
| Depreciation | 2.53 | 2.55 | 2.55 | 2.62 | 2.50 | 2.57 | 2.56 | 2.62 | 2.63 | 2.68 | 2.69 | 2.66 | 3.01 |
| Profit before tax | 1.36 | 4.78 | 5.07 | 7.91 | 9.54 | 8.56 | 8.61 | 3.34 | 7.48 | 7.05 | 7.49 | 3.17 | 5.28 |
| Tax % | 48.53% | 34.73% | 34.71% | 24.91% | 32.29% | 29.79% | 27.64% | 19.76% | 31.02% | 29.36% | 27.77% | 29.65% | 38.64% |
| Net Profit + | 0.70 | 3.12 | 3.31 | 5.93 | 6.46 | 6.01 | 6.23 | 2.68 | 5.16 | 4.98 | 5.41 | 2.23 | 3.24 |
| EPS in Rs | 2.32 | 10.32 | 10.95 | 19.61 | 21.37 | 19.88 | 20.61 | 8.86 | 17.07 | 16.47 | 17.89 | 7.38 | 10.72 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).